Literature DB >> 16837179

Effect of docosahexaenoic acid on tissue targeting and metabolism of plasma lipoproteins.

Alla Polozova1, Elisa Gionfriddo, Norman Salem.   

Abstract

We examined the effect of the docosahexaenoic acid (DHA) content of lipoproteins on their metabolism in vivo by a radioisotope labeling and tracking method. Purified HDL and LDL were labeled with (3)H-cholesteryl oleate tracer. To mimic dietary-related changes in fatty acid composition of lipoproteins, we incorporated lipids acylated with either DHA, arachidonic (AA) or oleic (OA) acid to phosphatidylcholine (didocosahexaenoylphosphatidylcholine (di22:6-PC), diarachidonoylphosphatidylcholine (di20:4-PC) and dioleoylphosphatidylcholine (di18:0-PC), respectively) into the purified particles. The lipids, at the amount added, did not cause detectable alterations in the morphology of the lipoproteins. Levels of radiotracers in blood and in several target tissues such as brain, heart, liver, muscle and adipose were determined at 1.5, 3 and 24h after intravenous injection into C57Bl/6J mice. No statistically significant differences were detected in the tissue distribution of tracers introduced into HDL enriched in DHA, compared to particles enriched with OA. In contrast, we found a significantly higher proportion of radiolabel associated with LDL enriched in DHA in heart, brown adipose and brain tissues. The uptake of labels associated with DHA containing LDL nearly doubled for heart and brown adipose tissues at 1.5 and 3h, and it was 30% higher for brain tissues at 24h. The tissue distribution of labels from the same particles enriched in AA or OA did not show a statistically significant difference from unaltered control lipoproteins. These findings point to the possible role of DHA in the regulation of LDL metabolism and involvement of the lipoproteins in transport of n-3 PUFA to target organs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837179     DOI: 10.1016/j.plefa.2006.05.009

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  8 in total

1.  Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.

Authors:  Mitchel A Kling; Dayan B Goodenowe; Vijitha Senanayake; Siamak MahmoudianDehkordi; Matthias Arnold; Tyler J Massaro; Rebecca Baillie; Xianlin Han; Yuk-Yee Leung; Andrew J Saykin; Kwangsik Nho; Alexandra Kueider-Paisley; Jessica D Tenenbaum; Li-San Wang; Leslie M Shaw; John Q Trojanowski; Rima F Kaddurah-Daouk
Journal:  Alzheimers Dement       Date:  2020-07-27       Impact factor: 21.566

2.  Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma.

Authors:  Jodianne T Wood; John S Williams; Lakshmipathi Pandarinathan; David R Janero; Carol J Lammi-Keefe; Alexandros Makriyannis
Journal:  J Lipid Res       Date:  2010-01-13       Impact factor: 5.922

3.  Streptozotocin-induced diabetes partially attenuates the effects of a high-fat diet on liver and brain fatty acid composition in mice.

Authors:  Beth Levant; Marlies K Ozias; Brianne L Guilford; Douglas E Wright
Journal:  Lipids       Date:  2013-07-28       Impact factor: 1.880

4.  Role of liver and plasma lipoproteins in selective transport of n-3 fatty acids to tissues: a comparative study of 14C-DHA and 3H-oleic acid tracers.

Authors:  Alla Polozova; Norman Salem
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

5.  Lipidomics of Alzheimer's disease: current status.

Authors:  Paul L Wood
Journal:  Alzheimers Res Ther       Date:  2012-02-01       Impact factor: 6.982

6.  Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.

Authors:  Paul L Wood; Tara Smith; Nina Lane; M Amin Khan; Greg Ehrmantraut; Dayan B Goodenowe
Journal:  Lipids Health Dis       Date:  2011-12-05       Impact factor: 3.876

7.  In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor.

Authors:  Paul L Wood; M Amin Khan; Tara Smith; Greg Ehrmantraut; Wei Jin; Wei Cui; Nancy E Braverman; Dayan B Goodenowe
Journal:  Lipids Health Dis       Date:  2011-10-18       Impact factor: 3.876

8.  Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.

Authors:  P Bougnoux; N Hajjaji; M N Ferrasson; B Giraudeau; C Couet; O Le Floch
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.